Wow, Ebola vaccine proved 100% protection against the deadly disease

image

An Ebola vaccine provided 100-percent protection in a field trial in hard-hit Guinea, researchers and officials said Friday, mooting “the beginning of the end” of the killer West African outbreak.

The world is “on the verge of an effective Ebola vaccine,” the World Health Organization (WHO) said, hailing the results from the first efficacy test of the VSV-ZEBOV vaccine among people living in a high-danger zone.

“This is an extremely promising development,” added WHO chief Margaret Chan.

“An effective vaccine will be another very important tool for both current and future Ebola outbreaks.”

About 28,000 people have been infected in Guinea, Sierra Leone and Liberia in the worst Ebola outbreak in history, according to the WHO, and more than 11,000 have died.

VSV-ZEBOV may become the first licensed vaccine against the disease for which there is also no approved treatment or cure.

The trial showed that the vaccine “offers 100 percent protection against Ebola after roughly one week,” said researcher Sven Trelle from the University of Bern.

The test, backed by drug firm Merck, the WHO and the governments of Canada, Norway and Guinea, saw 4,123 high-risk people vaccinated immediately after someone close to them fell ill with the deadly hemorrhagic fever.

None of the vaccinated group caught the virus, according to study results published in The Lancet medical journal.

A second, comparison group of 3,528 people received the vaccine only three weeks after potential exposure. Sixteen of them contracted the virus, said the study, but by day six after immunisation, the remainder of this group was also fully protected.

“Indeed, no vaccinee developed symptoms more than six days after vaccination, irrespective of whether vaccination was immediate or delayed,” said the study paper.

“The initial results of the study show that the vaccine can effectively contain the further spread of the Ebola virus,” added a statement from the University of Bern, which contributed to the research.

Disease experts welcomed the results.

This is big news – the most promising medical development so far in the ongoing race to shut down Ebola,” Benjamin Neuman, a virologist with the University of Reading, told AFP.

Added Peter Smith of the London School of Hygiene & Tropical Medicine, the results were “very exciting and suggest that the Ebola vaccine tested may be highly effective in protecting against Ebola disease among those in the immediate vicinity of an Ebola case.”

While the vaccine up to now shows 100% efficacy in individuals, more conclusive evidence is needed on its capacity to protect populations through what is called “herd immunity”.  To that end, the Guinean national regulatory authority and ethics review committee have approved continuation of the trial.   

“This is Guinea’s gift to West Africa and the world,” said Dr. Sakoba Keita, Guinea’s national coordinator for the Ebola response. “The thousands of volunteers from Conakry and other areas of Lower Guinea, but also the many Guinean doctors, data managers and community mobilisers have contributed to finding a line of defence against a terrible disease.”

About VSV-EBOV Ebola vaccine

VSV-EBOV is based in part on a genetically engineered version of vesicular stomatitis virus, which primarily affects rodents, cattle, swine and horses. Human VSV infections are rare and mild. In the VSV-EBOV investigational vaccine, the gene for the outer protein of VSV replaces the same gene segment of the Zaire Ebola virus species. Receiving the VSV-EBOV vaccine cannot cause an individual to become infected with Ebola.

Culled from AFP Report

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s